- ISIN
- US68213N1090
- CUSIP
- 68213N109
- Sector
- Healthcare
- Industry
- Health Information Services
- IPO Date
- Aug 7, 2001
Highlights
- Market Cap
- $1.78B
- Enterprise Value
- $1.73B
- EPS (TTM)
- $0.44
- PE Ratio
- 87.20
- PEG Ratio
- 5.21
- Total Revenue (TTM)
- $1.23B
- Gross Profit (TTM)
- $532.87M
- EBITDA (TTM)
- $98.25M
- Year Range
- $26.85 - $55.00
- Target Price
- $57.75
- ROA (TTM)
- 1.02%
- ROE (TTM)
- 1.63%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
OMCL Performance Chart
Omnicell, Inc. (OMCL) is down 14.6% since the beginning of the year. At $39 per share, OMCL is trading 29.7% below its 52-week high of $55. Investors who bought $1,000 worth of OMCL shares 5 years ago would now be looking at an investment worth $260.
Loading charts...
Returns By Period
Omnicell, Inc. (OMCL) has returned -14.61% so far this year and 38.00% over the past 12 months. Over the last ten years, OMCL has returned 1.45% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Omnicell, Inc.
- 1D
- -0.95%
- 1M
- -12.90%
- YTD
- -14.61%
- 6M
- -15.36%
- 1Y
- 38.00%
- 3Y*
- -17.98%
- 5Y*
- -23.63%
- 10Y*
- 1.45%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
OMCL Monthly Returns History
Based on dividend-adjusted daily data since Aug 9, 2001, OMCL's average daily return is +0.08%, while the average monthly return is +1.34%. At this rate, an investment would double in approximately 4.3 years.
Historically, 56% of months were positive and 44% were negative. The best month was Apr 2003 with a return of +78.7%, while the worst month was Oct 2002 at -48.6%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 6 months.
On a daily basis, OMCL closed higher 50% of trading days. The best single day was Aug 1, 2024 with a return of +33.0%, while the worst single day was Oct 8, 2002 at -47.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.06% | -15.26% | -18.78% | 24.09% | 6.57% | -12.37% | -14.61% | ||||||
| 2025 | 1.06% | -15.40% | -8.15% | -10.58% | -2.85% | -3.19% | 5.48% | 5.10% | -6.57% | 10.25% | 8.76% | 24.08% | 1.75% |
| 2024 | -14.51% | -18.43% | 11.39% | -8.28% | 21.56% | -16.94% | 7.91% | 52.28% | -1.98% | 11.56% | -4.21% | -4.44% | 18.31% |
| 2023 | 10.02% | -1.86% | 7.77% | 3.58% | 20.82% | 0.34% | -14.28% | -9.96% | -20.79% | -21.09% | -6.13% | 12.80% | -25.37% |
| 2022 | -16.79% | -13.89% | 0.16% | -15.69% | 1.82% | 2.33% | -3.19% | -7.11% | -14.92% | -11.16% | -33.25% | -2.31% | -72.06% |
| 2021 | -1.85% | 7.72% | 2.34% | 11.67% | -4.15% | 8.96% | -3.27% | 5.99% | -4.41% | 20.02% | -0.65% | 1.94% | 50.34% |
Benchmark Metrics
Omnicell, Inc. has an annualized alpha of 11.65%, beta of 0.93, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since August 09, 2001.
- This stock participated in 109.87% of S&P 500 Index downside but only 103.66% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 11.65%
- Beta
- 0.93
- R²
- 0.12
- Upside Capture
- 103.66%
- Downside Capture
- 109.87%
Return for Risk
Risk / Return Rank
OMCL ranks 65 for risk / return — better than 65% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Omnicell, Inc. (OMCL) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| OMCL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.24 | ||
| Sortino ratioReturn per unit of downside risk | -1.31 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.37 | -0.18 |
| Calmar ratioReturn relative to maximum drawdown | 1.03 | 2.78 | -1.75 |
| Martin ratioReturn relative to average drawdown | 2.43 | 12.44 | -10.01 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Omnicell, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Omnicell, Inc. was 86.67%, occurring on Oct 16, 2002. Recovery took 189 trading sessions.
The current Omnicell, Inc. drawdown is 78.93%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Dot-com crash2000–2002 | -86.67%Oct 2002 | 10mo 14d | 9mo 5d | 1y 7moDec 2001 - Jul 2003 |
2025 selloff2025 | -86.59%May 2025 | 3y 5mo | — | 4y 7moNov 2021 - now |
Financial crisis2007–2009 | -77.96%Mar 2009 | 1y 5mo | 5y 8mo | 7y 1moOct 2007 - Oct 2014 |
2005 bear market2005 | -72.92%May 2005 | 1y 2mo | 1y 11mo | 3y 1moMar 2004 - Apr 2007 |
Dot-com crash2000–2002 | -42.27%Sep 2001 | 14d | 2mo 15d | 2mo 29dSep 2001 - Dec 2001 |
Drawdown Indicators
| OMCL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -86.67% | -56.78% | -29.89% |
Max Drawdown (1Y)Largest decline over 1 year | -37.05% | -9.10% | -27.95% |
Max Drawdown (3Y)Largest decline over 3 years | -66.57% | -18.90% | -47.67% |
Max Drawdown (5Y)Largest decline over 5 years | -86.59% | -25.43% | -61.16% |
Max Drawdown (10Y)Largest decline over 10 years | -86.59% | -33.92% | -52.67% |
Current DrawdownCurrent decline from peak | -78.93% | -1.80% | -77.13% |
Average DrawdownAverage peak-to-trough decline | -37.36% | -10.71% | -26.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.69% | 2.03% | +13.66% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Omnicell, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Omnicell, Inc. is priced in the market compared to other companies in the Health Information Services industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for OMCL, comparing it with other companies in the Health Information Services industry. Currently, OMCL has a P/E ratio of 87.2. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for OMCL compared to other companies in the Health Information Services industry. OMCL currently has a PEG ratio of 5.2. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for OMCL relative to other companies in the Health Information Services industry. Currently, OMCL has a P/S ratio of 1.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for OMCL in comparison with other companies in the Health Information Services industry. Currently, OMCL has a P/B value of 1.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with OMCL
Add Omnicell, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with OMCL